Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352653 | 1.00 | ADRB2 (0.56) | ADRB2ALOX5PDE2AMAOACYP2A6 | |
| SCHEMBL256802 | 1.00 | ADRB2 (0.56) | ADRB2ALOX5PDE2AMAOACYP2A6 | |
| Hydrochloric Acid SCHEMBL9900692 | 0.97 | ADRB2 (0.54) | ADRB2ALOX5PDE2AMAOACYP2A6 | |
| Hydrochloric Acid SCHEMBL14977817 | 0.97 | ADRB2 (0.54) | ADRB2ALOX5PDE2AMAOACYP2A6 | |
| Iodide SCHEMBL29177617 | 0.97 | ADRB2 (0.54) | ADRB2ALOX5PDE2AMAOACYP2A6 | |
| Bromide SCHEMBL25277530 | 0.97 | ADRB2 (0.54) | ADRB2ALOX5PDE2AMAOACYP2A6 | |
| Hydrochloric Acid SCHEMBL2903958 | 0.97 | ADRB2 (0.54) | ADRB2ALOX5PDE2AMAOACYP2A6 | |
| Hexane SCHEMBL11623547 | 0.87 | ADRB2 (0.45) | ADRB2ALOX5PDE2AMAOAHTR2A | |
| SCHEMBL1314596 | 0.85 | ADRB2 (0.72) | ADRB2PDE2AALDH1A1ALOX15 | |
| SCHEMBL12280986 | 0.79 | ALOX5 (0.42) | ADRB2ALOX5MAOACYP2A6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040438-A | Isoxazole antiparasitic agents Synthesis method of medicine lotirana | 华南农业大学 | 2025-05-27 | — | — | CN | claimed |
| WO-2025104679-A1 | PROCESSES FOR MAKING INTERMEDIATES FOR ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-05-22 | — | — | WO | claimed |
| CN-118946165-A | Interface interaction spin-photon conversion body heterostructure and preparation method | 武汉大学 | 2024-11-12 | — | — | CN | claimed |
| CN-118922037-A | Chiral photoelectric functional material with wide band gap and preparation method thereof | 武汉大学 | 2024-11-08 | — | — | CN | claimed |
| CN-118745344-A | Perovskite circular polarization luminescent material with chiral low-dimensional-three-dimensional heterojunction structure and application thereof | 武汉大学 | 2024-10-08 | — | — | CN | claimed |
| US-12104106-B2 | Compositions of chiral molecules and perovskite nanocrystals and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2024-10-01 | — | — | US | claimed |
| CN-118125984-A | Benzenesulfonamide compound and preparation method and application thereof | 中国药科大学 | 2024-06-04 | — | — | CN | claimed |
| US-11760750-B1 | Process for preparing levoketoconazole | NURAY CHEMICALS PRIVATE LIMITED (IN) | 2023-09-19 | — | — | US | claimed |
| CN-114958368-B | Two-dimensional chiral organic-inorganic hybrid perovskite crystal and preparation method and application thereof | 闽都创新实验室 | 2023-08-01 | — | — | CN | claimed |
| US-20220326082-A1 | CHIRAL HETEROSTRUCTURES | Alliance for Energy Innovation, LLC | 2022-10-13 | — | — | US | claimed |
| EP-2385983-A2 | TRANSAMINASE POLYPEPTIDES | Codexis, Inc. (US) | 2011-11-16 | — | — | EP | claimed |
| US-D646886-S1 | Tip of an umbrella | Pro Performance Sports, L.L.C. (US) | 2011-10-18 | — | — | US | claimed |
| US-20100209981-A1 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-08-19 | — | — | US | claimed |
| WO-2010081053-A2 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-07-15 | — | — | WO | claimed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | claimed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | ADRB2 1490/4885ALOX5 717/4885PDE2A 2285/4885 |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | ADRB2 1661/4885ALOX5 1639/4885PDE2A 3676/4885 |
| US-11760750-B1 | Process for preparing levoketoconazole | KHK, KYAT3, PLK3 | ADRB2 1631/4885ALOX5 1572/4885PDE2A 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.